NEW YORK (GenomeWeb News) – Scientists in the Czech Republic and Slovakia will use a breast cancer test from OncoVista Innovative Therapies subsidiary AdnaGen in a cancer research effort focused on using the predictive assay in clinics, the San Antonio-based firm said today.

Under the agreement, Tataa Molecular Diagnostics will partner with the Institute of Biotechnology of the Czech Academy of Science on the COHERTA study, which is funded in part through a grant from Hoffman-La Roche's Czech and Slovak subsidiaries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.